{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:54Z","timestamp":1793812674217,"version":"4.6.1"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011962","name":"Research Center for Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116193","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:58:16Z","timestamp":1769032696000},"page":"116193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies"],"prefix":"10.1016","volume":"172","author":[{"given":"Sepideh","family":"Gholami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa Shiri","family":"Aghbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Zenderuh","family":"Ravanlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz Baghban","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein Bannazadeh","family":"Baghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116193_bb0005","article-title":"HPV-specific antivirals: disarming viral entry and disruption of replication","author":"Ravanlo","year":"2025","journal-title":"The Microbe"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0010","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ijgc-2022-003957","article-title":"Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services","volume":"33","author":"Dzinamarira","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2026.116193_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25147616","article-title":"HPV infections-classification, pathogenesis, and potential new therapies","volume":"25","author":"Mlynarczyk-Bonikowska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12985-023-02106-y","article-title":"Human papillomavirus spectrum of HPV-infected women in Nigeria: an analysis by next-generation sequencing and type-specific PCR","volume":"20","author":"Dom-Chima","year":"2023","journal-title":"Virol. J."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.21147\/j.issn.1000-9604.2018.02.04","article-title":"Systemic therapy for cervical carcinoma - current status","volume":"30","author":"Serkies","year":"2018","journal-title":"Chin. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094943","article-title":"HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation","volume":"23","author":"Yu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116193_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107331","article-title":"The role of Th17 cells in viral infections","volume":"91","author":"Aghbash","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/v9080232","article-title":"Human papillomavirus and the DNA damage response: exploiting host repair pathways for viral replication","volume":"9","author":"Spriggs","year":"2017","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-10-2626","article-title":"Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases","volume":"71","author":"Bodily","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12030402","article-title":"Targeting mitochondrial therapy in the regulation of HPV infection and HPV-related cancers","volume":"12","author":"Cruz-Gregorio","year":"2023","journal-title":"Pathogens"},{"issue":"20","key":"10.1016\/j.intimp.2026.116193_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells14201629","article-title":"HPV oncoproteins and mitochondrial reprogramming: the central role of ROMO1 in oxidative stress and metabolic shifts","volume":"14","author":"Tsoneva","year":"2025","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0060","first-page":"188","article-title":"Immunology of cervical cancer","volume":"72","author":"Manzo-Merino","year":"2020","journal-title":"Rev. Investig. Clin."},{"issue":"18","key":"10.1016\/j.intimp.2026.116193_bb0065","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical Cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb0070","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.bjc.6605344","article-title":"Gene silencing of HPV16 E6\/E7 induced by promoter-targeting siRNA in SiHa cells","volume":"101","author":"Hong","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116193_bb0075","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002296","article-title":"Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes","volume":"6","author":"Dey","year":"2025","journal-title":"Explor. Target Antitumor Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 (HPV16) and HPV18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody","volume":"12","author":"Peng","year":"2021","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0085","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/jcm4051126","article-title":"Human papillomavirus: current and future RNAi therapeutic strategies for cervical Cancer","volume":"4","author":"Jung","year":"2015","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70075","article-title":"Synergy effects of HPV E6-E7 encoding mRNA and nucleic acid Immunostimulators improve therapeutic potential in TC-1 graft tumor","volume":"96","author":"He","year":"2024","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/1389557522666220128155525","article-title":"Resveratrol and cervical Cancer: a new therapeutic option","volume":"23","author":"Shafabakhsh","year":"2023","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116193_bb0100","doi-asserted-by":"crossref","first-page":"1037124","DOI":"10.3389\/fimmu.2022.1037124","article-title":"Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116193_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.904790","article-title":"Monoclonal antibodies in cervical malignancy-related HPV","volume":"12","author":"Aghbash","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12951-021-00970-w","article-title":"CRISPR\/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer","volume":"19","author":"Li","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13353-024-00883-y","article-title":"HPV-driven oncogenesis-much more than the E6 and E7 oncoproteins","volume":"66","author":"Janiszewska","year":"2025","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.intimp.2026.116193_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2023.109946","article-title":"Computational and AI-driven 3D structural analysis of human papillomavirus (HPV) oncoproteins E5, E6, and E7 reveal significant divergence of HPV E5 between low-risk and high-risk genotypes","volume":"590","author":"Jones","year":"2024","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.001","article-title":"HPV16 E7 genetic conservation is critical to carcinogenesis","volume":"170","author":"Mirabello","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02033-22","article-title":"ZER1 contributes to the carcinogenic activity of high-risk HPV E7 proteins","volume":"13","author":"Nouel","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.intimp.2026.116193_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.955847","article-title":"Role of HPV16 E1 in cervical carcinogenesis","volume":"12","author":"Baedyananda","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14218\/ERHM.2023.00053","article-title":"Cancers associated with human papillomavirus: an overview of prevalence in Iran and the Middle East","volume":"9","author":"Baghi","year":"2024","journal-title":"Exploratory Res. Hypothesis Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftz048","article-title":"Association of human papillomavirus infection and inflammation in cervical cancer","volume":"77","author":"Hemmat","year":"2019","journal-title":"Pathog. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12935-020-01594-0","article-title":"E2F1\/2\/7\/8 as independent indicators of survival in patients with cervical squamous cell carcinoma","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/v13101892","article-title":"The not-so-good, the bad and the ugly: HPV E5, E6 and E7 oncoproteins in the orchestration of carcinogenesis","volume":"13","author":"Basukala","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2008.07.017","article-title":"Direct association of the HPV16 E7 oncoprotein with cyclin A\/CDK2 and cyclin E\/CDK2 complexes","volume":"380","author":"Nguyen","year":"2008","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.onc.1204130","article-title":"Regulation of the Cdc25A gene by the human papillomavirus type 16 E7 oncogene","volume":"20","author":"Katich","year":"2001","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00432-023-05511-6","article-title":"Human papillomavirus E7 protein induces homologous recombination defects and PARPi sensitivity","volume":"150","author":"He","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"39","key":"10.1016\/j.intimp.2026.116193_bb0175","doi-asserted-by":"crossref","first-page":"19552","DOI":"10.1073\/pnas.1906102116","article-title":"Human papillomavirus E7 oncoprotein targets RNF168 to hijack the host DNA damage response","volume":"116","author":"Sitz","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.intimp.2026.116193_bb0180","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1073\/pnas.1819534116","article-title":"PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis","volume":"116","author":"Hatterschide","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"32","key":"10.1016\/j.intimp.2026.116193_bb0185","doi-asserted-by":"crossref","first-page":"11492","DOI":"10.1073\/pnas.0505337102","article-title":"Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600","volume":"102","author":"Huh","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11091027","article-title":"Do or die: HPV E5, E6 and E7 in cell death evasion","volume":"11","author":"Skelin","year":"2022","journal-title":"Pathogens"},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0195","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1541-7786.MCR-19-1114","article-title":"miR-106a regulates cell proliferation and autophagy by targeting LKB1 in HPV-16-associated cervical Cancer","volume":"18","author":"Cui","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008624","article-title":"MicroRNA-18a targeting of the STK4\/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer","volume":"16","author":"Morgan","year":"2020","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033585","article-title":"HPV16 oncoproteins induce MMPs\/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis","volume":"7","author":"Cardeal","year":"2012","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.intimp.2026.116193_bb0215","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1128\/JVI.02363-07","article-title":"Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins","volume":"82","author":"Yoshida","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2026.116193_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2023.102041","article-title":"Induction of epithelial to mesenchymal transition in HPV16 E6\/E7 oncogene transfected C33A cell line","volume":"82","author":"Chakraborti","year":"2023","journal-title":"Tissue Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3892\/ol.2011.512","article-title":"The role of human papillomavirus type 16 E6\/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis","volume":"3","author":"Cheng","year":"2012","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020353","article-title":"Physical Interaction between HPV16E7 and the Actin-Binding Protein Gelsolin Regulates Epithelial-Mesenchymal Transition via HIPPO-YAP Axis","volume":"13","author":"Matarrese","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102297","article-title":"Role of the JAK\/STAT pathway in cervical Cancer: its relationship with HPV E6\/E7 oncoproteins","volume":"9","author":"Guti\u00e9rrez-Hoya","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0240","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170111","article-title":"Upregulation of PIR gene expression induced by human papillomavirus E6 and E7 in epithelial oral and cervical cells","volume":"7","author":"Carrillo","year":"2017","journal-title":"Open Biol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.32604\/or.2022.026776","article-title":"The effect of Wnt\/\u03b2-catenin signaling on PD-1\/PDL-1 axis in HPV-related cervical cancer","volume":"30","author":"Aghbash","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.intimp.2026.116193_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2021.200213","article-title":"Human papillomavirus E6 and E7: what remains?","volume":"11","author":"Vats","year":"2021","journal-title":"Tumour Virus Res."},{"key":"10.1016\/j.intimp.2026.116193_bb0255","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: the cervical Cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front. Microbiol."},{"issue":"6260","key":"10.1016\/j.intimp.2026.116193_bb0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.aab3291","article-title":"DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway","volume":"350","author":"Lau","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","article-title":"Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb0270","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/sj.emboj.7600651","article-title":"HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs","volume":"24","author":"Longworth","year":"2005","journal-title":"EMBO J."},{"issue":"15","key":"10.1016\/j.intimp.2026.116193_bb0275","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.7150\/ijbs.50074","article-title":"HPV E7 inhibits cell pyroptosis by promoting TRIM21-mediated degradation and ubiquitination of the IFI16 inflammasome","volume":"16","author":"Song","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"22","key":"10.1016\/j.intimp.2026.116193_bb0280","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1128\/JVI.02151-15","article-title":"Downregulation of toll-like receptor 9 expression by Beta human papillomavirus 38 and implications for cell cycle control","volume":"89","author":"Pacini","year":"2015","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0285","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.20122394","article-title":"The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the toll-like receptor 9 promoter","volume":"210","author":"Hasan","year":"2013","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0290","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1128\/JVI.01942-05","article-title":"Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner","volume":"80","author":"James","year":"2006","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0295","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virol.2011.12.023","article-title":"Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization","volume":"425","author":"Vandermark","year":"2012","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01812-19","article-title":"Human papillomavirus E7 oncoprotein subverts host innate immunity via SUV39H1-mediated epigenetic silencing of immune sensor genes","volume":"94","author":"Lo Cigno","year":"2020","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9040292","article-title":"Subversion of host innate immunity by human papillomavirus oncoproteins","volume":"9","author":"Lo Cigno","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2026.116193_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2022.109449","article-title":"Human papillomavirus 16 E6\/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p\/PD-L1 axis","volume":"731","author":"Ling","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"issue":"44","key":"10.1016\/j.intimp.2026.116193_bb0315","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1038\/sj.onc.1209584","article-title":"Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7","volume":"25","author":"Ohlenschl\u00e4ger","year":"2006","journal-title":"Oncogene"},{"issue":"31","key":"10.1016\/j.intimp.2026.116193_bb0320","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1038\/onc.2013.426","article-title":"A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c)","volume":"33","author":"Pang","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116193_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2024.200300","article-title":"The HPV101 E7 protein shares host cellular targets and biological activities with high-risk HPV16 E7","volume":"19","author":"Gelbard","year":"2025","journal-title":"Tumour Virus Res."},{"issue":"24","key":"10.1016\/j.intimp.2026.116193_bb0330","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1128\/JVI.01637-12","article-title":"Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor","volume":"86","author":"Todorovic","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2026.116193_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2023.200270","article-title":"Identification and characterisation of novel potential phospho-acceptor sites in HPV-16 E7","volume":"16","author":"Trejo-Cerro","year":"2023","journal-title":"Tumour Virus Res."},{"issue":"14","key":"10.1016\/j.intimp.2026.116193_bb0340","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/cbic.201300172","article-title":"The heterogeneous structural behavior of E7 from HPV16 revealed by NMR spectroscopy","volume":"14","author":"Cal\u00e7ada","year":"2013","journal-title":"Chembiochem"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0345","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/bi0522549","article-title":"Chaperone holdase activity of human papillomavirus E7 oncoprotein","volume":"45","author":"Alonso","year":"2006","journal-title":"Biochemistry"},{"issue":"19","key":"10.1016\/j.intimp.2026.116193_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194895","article-title":"HPV16 E7 Nucleotide Variants Found in Cancer-Free Subjects Affect E7 Protein Expression and Transformation","volume":"14","author":"Lou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.116193_bb0355","article-title":"T cell immunotherapy for cervical cancer: challenges and opportunities","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/CCO.0000000000000663","article-title":"Advances in immunotherapy for cervical cancer","volume":"32","author":"Wendel Naumann","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0365","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J. Gynecol. Oncol."},{"issue":"30","key":"10.1016\/j.intimp.2026.116193_bb0370","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0375","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/0929867327666200128105459","article-title":"The roles of programmed cell death Ligand-1\/ programmed cell Death-1 (PD-L1\/PD-1) in HPV-induced cervical Cancer and potential for their use in blockade therapy","volume":"28","author":"Zhang","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.intimp.2026.116193_bb0380","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2024.05.006","article-title":"Identification of HPV-E7 specific TCRs for tumor immunotherapy","volume":"171","author":"Li","year":"2024","journal-title":"Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0385","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","article-title":"CARs: synthetic immunoreceptors for Cancer therapy and beyond","volume":"23","author":"Chang","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0390","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116193_bb0395","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clim.2016.07.006","article-title":"Metastatic melanoma and immunotherapy","volume":"172","author":"Herzberg","year":"2016","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0400","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejcsup.2013.07.013","article-title":"Immunotherapy of melanoma","volume":"11","author":"Haanen","year":"2013","journal-title":"EJC Suppl."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0405","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","article-title":"TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges","volume":"22","author":"Golikova","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0410","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0415","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0420","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0425","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.116193_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2020.110403","article-title":"Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer","volume":"505","author":"Cho","year":"2020","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.intimp.2026.116193_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216242","article-title":"A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7","volume":"566","author":"Poorebrahim","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0440","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/s41467-024-46558-4","article-title":"HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice","volume":"15","author":"Long","year":"2024","journal-title":"Nat. Commun."},{"issue":"6334","key":"10.1016\/j.intimp.2026.116193_bb0445","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovi\u0107","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0450","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116193_bb0455","doi-asserted-by":"crossref","unstructured":"A. A. Jazaeri et al., Safety and Efficacy of Adoptive Cell Transfer Using Autologous Tumor Infiltrating Lymphocytes (LN-145) for Treatment of Recurrent, Metastatic, or Persistent Cervical Carcinoma, Ed: American Society of Clinical Oncology, 2019.","DOI":"10.1016\/j.ygyno.2018.04.274"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010263","article-title":"Towards novel gene and Cell therapy approaches for cervical cancer","volume":"15","author":"Polten","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0470","article-title":"CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer","volume":"32","author":"Duan","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0475","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0480","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0485","article-title":"New perspectives in therapeutic vaccines for HPV: a critical review","volume":"58","author":"Gardella","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.intimp.2026.116193_bb0490","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpobgyn.2017.09.008","article-title":"Therapeutic HPV vaccines","volume":"47","author":"Hancock","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0495","doi-asserted-by":"crossref","first-page":"18713","DOI":"10.1038\/s41598-019-55014-z","article-title":"A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0500","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s40136-023-00443-8","article-title":"Therapeutic vaccination for HPV-mediated cancers","volume":"11","author":"Yan","year":"2023","journal-title":"Curr. Otorhinolaryngol. Rep."},{"key":"10.1016\/j.intimp.2026.116193_bb0505","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virusres.2016.12.002","article-title":"The current state of therapeutic and T cell-based vaccines against human papillomaviruses","volume":"231","author":"Yang","year":"2017","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0510","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10637-023-01342-x","article-title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors","volume":"41","author":"Jimeno","year":"2023","journal-title":"Investig. New Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0515","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular vaccine approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2026.116193_bb0520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0525","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1423-0127-17-88","article-title":"Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation","volume":"17","author":"Wu","year":"2010","journal-title":"J. Biomed. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0530","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116193_bb0535","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Res."},{"issue":"19","key":"10.1016\/j.intimp.2026.116193_bb0540","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0545","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related Cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.intimp.2026.116193_bb0550","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116193_bb0555","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0560","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11532810-000000000-00000","article-title":"Immunotherapy for cervical cancer: research status and clinical potential","volume":"24","author":"Su","year":"2010","journal-title":"BioDrugs"},{"issue":"27","key":"10.1016\/j.intimp.2026.116193_bb0565","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/S0264-410X(01)00086-X","article-title":"Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens","volume":"19","author":"van der Burg","year":"2001","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.intimp.2026.116193_bb0570","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.vaccine.2019.04.043","article-title":"Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease","volume":"37","author":"Da Silva","year":"2019","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.intimp.2026.116193_bb0575","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0580","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01051.x","article-title":"Cytoplasmic DNA innate immune pathways","volume":"243","author":"Barber","year":"2011","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0585","article-title":"The Efficacy of Therapeutic DNA Vaccines Expressing the Human Papillomavirus E6 and E7 Oncoproteins for Treatment of Cervical Cancer: Systematic Review","volume":"10","author":"Akhatova","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116193_bb0595","doi-asserted-by":"crossref","first-page":"113","DOI":"10.21775\/cimb.022.113","article-title":"mRNA: a versatile molecule for Cancer vaccines","volume":"22","author":"Diken","year":"2017","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0600","article-title":"A Comparison of Plasmid DNA and mRNA as Vaccine Technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0605","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116193_bb0610","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"issue":"10008","key":"10.1016\/j.intimp.2026.116193_bb0615","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"7823","key":"10.1016\/j.intimp.2026.116193_bb0620","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"30","key":"10.1016\/j.intimp.2026.116193_bb0625","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0630","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","article-title":"A randomized phase 2 study of ADXS11-001 listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical Cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0635","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10238-024-01470-5","article-title":"Viral vector-based therapeutic HPV vaccines","volume":"24","author":"Ji","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116193_bb0640","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic vaccines for HPV-associated malignancies","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.intimp.2026.116193_bb0645","article-title":"An update on human papilloma virus vaccines: history, types, protection, and efficacy","volume":"12","author":"Yousefi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116193_bb0650","article-title":"Current status and future directions for the development of human papillomavirus vaccines","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0655","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2008.11.099","article-title":"Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity","volume":"27","author":"Karanam","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0660","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00705-017-3647-z","article-title":"Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells","volume":"163","author":"Baghban Rahimi","year":"2018","journal-title":"Arch. Virol."},{"issue":"6669","key":"10.1016\/j.intimp.2026.116193_bb0665","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116193_bb0670","series-title":"Delivery of RNA Interfering Effectors against HPV-16 E6 and E7 Proteins in OSCC Cells","author":"Ahmed","year":"2023"},{"issue":"sup2","key":"10.1016\/j.intimp.2026.116193_bb0675","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/21691401.2018.1468770","article-title":"The combinational effect of E6\/E7 siRNA and anti-miR-182 on apoptosis induction in HPV16-positive cervical cells","volume":"46","author":"Javadi","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0680","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/sj.cgt.7701118","article-title":"New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer","volume":"15","author":"Yamato","year":"2008","journal-title":"Cancer Gene Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0685","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0690","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2008.144","article-title":"Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic","volume":"16","author":"Giering","year":"2008","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0695","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47090759","article-title":"Emerging therapeutic strategies for HPV-related cancers: from gene editing to precision oncology","volume":"47","author":"Cakir","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"14","key":"10.1016\/j.intimp.2026.116193_bb0700","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.onc.1209244","article-title":"Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells","volume":"25","author":"Tang","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0705","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2011.10.028","article-title":"Transcriptional gene silencing of HPV16 E6\/E7 induces growth inhibition via apoptosis in vitro and in vivo","volume":"124","author":"Zhou","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116193_bb0710","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/cgt.2010.38","article-title":"Highly potent and specific siRNAs against E6 or E7 genes of HPV16-or HPV18-infected cervical cancers","volume":"17","author":"Chang","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0715","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/sj.cgt.7700971","article-title":"Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes","volume":"13","author":"Gu","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0720","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/JVI.78.8.4063-4073.2004","article-title":"Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells","volume":"78","author":"Horner","year":"2004","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0725","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10495-007-0163-8","article-title":"RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53","volume":"13","author":"Sima","year":"2008","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0730","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/sj.gt.3302645","article-title":"Antiviral RNAi therapy: emerging approaches for hitting a moving target","volume":"13","author":"Leonard","year":"2006","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16070880","article-title":"Cationic liposomes carrying HPV16 E6-siRNA inhibit the proliferation, migration, and invasion of cervical Cancer cells","volume":"16","author":"S\u00e1nchez-Meza","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0740","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/ph18060864","article-title":"Engineering lipid-polymer nanoparticles for siRNA delivery to cancer cells","volume":"18","author":"Manda","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0750","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1073\/pnas.1322937111","article-title":"Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates","volume":"111","author":"Dong","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0755","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17425247.2020.1747429","article-title":"Delivery of genome editing tools: a promising strategy for HPV-related cervical malignancy therapy","volume":"17","author":"Aghamiri","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.intimp.2026.116193_bb0760","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtn.2019.10.045","article-title":"Therapeutic potential of LNP-mediated delivery of miR-634 for Cancer therapy","volume":"19","author":"Gokita","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298815","article-title":"Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6\/E7 combined with cisplatin in a xenograft model of cervical cancer","volume":"19","author":"Kang","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0770","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0775","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/cgt.2010.72","article-title":"Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs","volume":"18","author":"Gu","year":"2011","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0780","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.antiviral.2013.03.010","article-title":"Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes","volume":"98","author":"Zhou","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.intimp.2026.116193_bb0785","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2019.07.010","article-title":"Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment","volume":"214","author":"Cummings","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2026.116193_bb0790","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1175958","article-title":"Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12","volume":"13","author":"Deng","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116193_bb0795","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.3390\/ijms160612243","article-title":"Human papillomavirus E6\/E7-specific siRNA potentiates the effect of radiotherapy for cervical Cancer in vitro and in vivo","volume":"16","author":"Jung","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0800","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/ijc.26197","article-title":"The synergistic therapeutic effect of cisplatin with human papillomavirus E6\/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo","volume":"130","author":"Jung","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116193_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148904","article-title":"Novel strategies in HPV-16-related cervical cancer treatment: An in vitro study of combined siRNA-E5 with oxaliplatin and ifosfamide chemotherapy","volume":"932","author":"Rasizadeh","year":"2025","journal-title":"Gene"},{"issue":"6096","key":"10.1016\/j.intimp.2026.116193_bb0810","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0815","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cell.2017.02.018","article-title":"SnapShot: class 1 CRISPR-Cas systems","volume":"168","author":"Makarova","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116193_bb0820","article-title":"Towards the elimination of infectious HPV: exploiting CRISPR\/Cas innovations","volume":"15","author":"Liu","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0825","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-018-08224-4","article-title":"Engineering of CRISPR-Cas12b for human genome editing","volume":"10","author":"Strecker","year":"2019","journal-title":"Nat. Commun."},{"issue":"7546","key":"10.1016\/j.intimp.2026.116193_bb0830","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116193_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112743","article-title":"Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections","volume":"148","author":"Najafi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.intimp.2026.116193_bb0840","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"18","key":"10.1016\/j.intimp.2026.116193_bb0845","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1039\/D1BM00537E","article-title":"Harnessing lipid nanoparticles for efficient CRISPR delivery","volume":"9","author":"Yan","year":"2021","journal-title":"Biomater. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0850","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1039\/D1BM01658J","article-title":"Non-viral delivery of the CRISPR\/Cas system: DNA versus RNA versus RNP","volume":"10","author":"Lin","year":"2022","journal-title":"Biomater. Sci."},{"issue":"16","key":"10.1016\/j.intimp.2026.116193_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168537","article-title":"Nanotechnology-based strategies to overcome current barriers in gene delivery","volume":"22","author":"Mir\u00f3n-Barroso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0860","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41598-022-06025-w","article-title":"Antiproliferative effects of AAV-delivered CRISPR\/Cas9-based degradation of the HPV18-E6 gene in HeLa cells","volume":"12","author":"Noroozi","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0865","article-title":"Adenoviral vectors armed with PAPILLOMAVIRUs oncogene specific CRISPR\/Cas9 kill human-papillomavirus-induced cervical","volume":"12","author":"Ehrke-Schulz","year":"2020","journal-title":"Cancer Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0870","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2021.06.003","article-title":"New approaches to moderate CRISPR-Cas9 activity: addressing issues of cellular uptake and endosomal escape","volume":"30","author":"van Hees","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116193_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb0880","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1021\/acs.biomac.5c00954","article-title":"Construction of ROS-responsive poly(\u03b2-amino ester)-poly(\u03b2-thioether ester) copolymer for enhancing gene delivery and gene therapy","volume":"26","author":"Li","year":"2025","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010154","article-title":"Chitosan-functionalized poly(\u03b2-amino Ester) hybrid system for gene delivery in vaginal mucosal epithelial cells","volume":"16","author":"Gao","year":"2024","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb0890","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41417-021-00366-w","article-title":"The application of CRISPR\/Cas9 system in cervical carcinogenesis","volume":"29","author":"Gao","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.intimp.2026.116193_bb0895","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.ymthe.2019.08.012","article-title":"Systemic delivery of CRISPR\/Cas9 targeting HPV oncogenes is effective at eliminating established Tumors","volume":"27","author":"Jubair","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0900","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28144","article-title":"CRISPR\/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer","volume":"95","author":"Zhen","year":"2023","journal-title":"J. Med. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb0905","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28934","article-title":"Systemic delivery of specific and efficient CRISPR\/Cas9 system targeting HPV16 oncogenes using LL-37 antimicrobial peptide in C57BL\/6 mice","volume":"95","author":"Khairkhah","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2026.116193_bb0910","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jconrel.2023.07.007","article-title":"Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy","volume":"360","author":"Ling","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0915","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12985-025-02783-x","article-title":"HPV-driven cancers: a looming threat and the potential of CRISPR\/Cas9 for targeted therapy","volume":"22","author":"Kermanshahi","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2026.116193_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.148527","article-title":"In vitro study of HPV18-positive cervical cancer HeLa cells based on CRISPR\/Cas13a system","volume":"921","author":"Zhang","year":"2024","journal-title":"Gene"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0925","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/amh70040041","article-title":"Genome editing against HPV-driven cancers: from bench to clinic","volume":"70","author":"Cakir","year":"2025","journal-title":"Acta Microbiologica Hellenica"},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb0930","first-page":"2197","article-title":"CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6","volume":"17","author":"Yoshiba","year":"2019","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091197","article-title":"Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR\/Cas9","volume":"16","author":"Kim","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0940","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.116193_bb0945","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/jnci\/djn199","article-title":"Back to nature: extinction of medicinal plants threatens drug discovery","volume":"100","author":"Brower","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0950","article-title":"Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers","volume":"12","author":"Franconi","year":"2020"},{"issue":"3","key":"10.1016\/j.intimp.2026.116193_bb0955","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1166\/jbmb.2024.2380","article-title":"Research Progress of natural source potential drugs in reversing cervical precancerous lesions and human papillomavirus negative conversion","volume":"18","author":"Wang","year":"2024","journal-title":"J. Biobaased Mater. Bioenergy"},{"key":"10.1016\/j.intimp.2026.116193_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2025.106873","article-title":"The potential of polyphenols and polyphenol-rich extracts against human papillomavirus infections and associated cancers","volume":"129","author":"Arab","year":"2025","journal-title":"J. Funct. Foods"},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23092334","article-title":"Suppressive effects of EGCG on cervical Cancer","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0970","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12935-023-03161-9","article-title":"Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns","volume":"23","author":"Wang","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"13","key":"10.1016\/j.intimp.2026.116193_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28135246","article-title":"Epigallocatechin-3-gallate therapeutic potential in Cancer: mechanism of action and clinical implications","volume":"28","author":"Kciuk","year":"2023","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.intimp.2026.116193_bb0980","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115251","article-title":"Oral treatment with EGCG, folic acid, vitamin B12, and hyaluronic acid improves HPV clearance and counteracts its persistence: a clinical study","volume":"26","author":"Porcaro","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb0985","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12091897","article-title":"Treatment with epigallocatechin gallate, folic acid, vitamin B12, and hyaluronic acid decreases HPV positivity in women attending regional screening in Puglia","volume":"12","author":"Tinelli","year":"2024","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb0990","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1038\/s41598-020-65446-7","article-title":"Structural dynamic studies on identification of EGCG analogues for the inhibition of human papillomavirus E7","volume":"10","author":"Aarthy","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb0995","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10040459","article-title":"The major constituent of green tea, Epigallocatechin-3-gallate (EGCG), inhibits the growth of HPV18-infected keratinocytes by stimulating proteasomal turnover of the E6 and E7 oncoproteins","volume":"10","author":"Yap","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.intimp.2026.116193_bb1000","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1592395","article-title":"Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential","volume":"16","author":"Asiri","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116193_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114590","article-title":"Basic research on curcumin in cervical cancer: Progress and perspectives","volume":"162","author":"Zhang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116193_bb1010","series-title":"10 Curcumin\u2014Biological and Medicinal Properties","author":"Aggarwal","year":"2006"},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-009-0025-5","article-title":"Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells","volume":"325","author":"Singh","year":"2009","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12985-025-02738-2","article-title":"Curcumin nanoemulsion suppresses HPV oncogenes and inhibits cervical cancer progression: in vitro and in vivo study","volume":"22","author":"Karimi","year":"2025","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13008-024-00138-6","article-title":"Curcumin enhances ATG3-dependent autophagy and inhibits metastasis in cervical carcinoma","volume":"19","author":"Zheng","year":"2024","journal-title":"Cell Div"},{"issue":"2 Pt B","key":"10.1016\/j.intimp.2026.116193_bb1030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.canlet.2014.09.037","article-title":"Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer","volume":"356","author":"Munagala","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116193_bb1035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.biopha.2018.06.028","article-title":"Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity","volume":"105","author":"Qin","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1040","doi-asserted-by":"crossref","DOI":"10.3390\/v17010055","article-title":"Plant compounds inhibit the growth of W12 cervical precancer cells containing Episomal or integrant HPV DNA; Tanshinone IIA synergizes with curcumin in cervical Cancer cells","volume":"17","author":"Einbond","year":"2024","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.intimp.2026.116193_bb1045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29102277","article-title":"Carvacrol and thymol hybrids: potential anticancer and antibacterial therapeutics","volume":"29","author":"Peter","year":"2024","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.intimp.2026.116193_bb1050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13205-025-04250-4","article-title":"Targeting the interplay between human papillomavirus oncoproteins and hedgehog signaling: assessment of chemopreventive potential of carvacrol in cervical cancer","volume":"15","author":"Ahmad","year":"2025","journal-title":"3 Biotech"},{"key":"10.1016\/j.intimp.2026.116193_bb1055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.09.048","article-title":"Berberine alters epigenetic modifications, disrupts microtubule network, and modulates HPV-18 E6-E7 oncoproteins by targeting p53 in cervical cancer cell HeLa: a mechanistic study including molecular docking","volume":"744","author":"Saha","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116193_bb1060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1476-4598-10-39","article-title":"Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells","volume":"10","author":"Mahata","year":"2011","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2026.116193_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27144523","article-title":"Anticancer effects and mechanisms of berberine from medicinal herbs: An update review","volume":"27","author":"Xiong","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.116193_bb1070","series-title":"Exploring the role of berberine as anti-cancer agent in cervical cancer","author":"Brunda","year":"2025"},{"key":"10.1016\/j.intimp.2026.116193_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216584","article-title":"Magnolin targeting of the JNK\/Sp1\/MMP15 signaling axis suppresses cervical cancer microenvironment and metastasis via microbiota modulation","volume":"583","author":"Lin","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb1080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ijc.25679","article-title":"Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study","volume":"129","author":"Gonz\u00e1lez","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb1085","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.7314\/APJCP.2015.16.7.2981","article-title":"Serum carotenoid, retinol and tocopherol concentrations and risk of cervical cancer among Chinese women","volume":"16","author":"Zhang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"9","key":"10.1016\/j.intimp.2026.116193_bb1090","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jiph.2023.06.016","article-title":"Natural and synthetic drugs and formulations for intravaginal HPV clearance","volume":"16","author":"Khamjan","year":"2023","journal-title":"J. Infect. Public Health"},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb1095","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21070901","article-title":"Polyphenols: extraction methods, antioxidative action, bioavailability and anticarcinogenic effects","volume":"21","author":"Brglez Mojzer","year":"2016","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb1100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.coi.2010.12.010","article-title":"Therapeutic vaccination against human papilloma virus induced malignancies","volume":"23","author":"Van Der Burg","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2026.116193_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104721","article-title":"Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer","volume":"211","author":"Ranasinghe","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"20","key":"10.1016\/j.intimp.2026.116193_bb1110","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J. Virol."},{"issue":"Pt 11","key":"10.1016\/j.intimp.2026.116193_bb1115","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1099\/vir.0.054486-0","article-title":"Human papillomavirus 16-encoded E7 protein inhibits IFN-\u03b3-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes","volume":"94","author":"Zhou","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.intimp.2026.116193_bb1120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virusres.2016.11.023","article-title":"Evasion of host immune defenses by human papillomavirus","volume":"231","author":"Westrich","year":"2017","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1125","first-page":"22","article-title":"Cervical cancer immune microenvironment: mechanisms of HPV-mediated immune evasion and advances in immunotherapy (review)","volume":"31","author":"Zhou","year":"2026","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2026.116193_bb1130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12032-023-01997-9","article-title":"Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients","volume":"40","author":"Das","year":"2023","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116193_bb1135","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","article-title":"Blocking TIGIT\/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer","volume":"20","author":"Liu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2026.116193_bb1140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/rmv.1823","article-title":"Signaling pathways in HPV-associated cancers and therapeutic implications","volume":"25","author":"Chen","year":"2015","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116193_bb1145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12032-022-01942-2","article-title":"Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer","volume":"40","author":"Wang","year":"2023","journal-title":"Med. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2026.116193_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233911","article-title":"Reduced MHC class I and II expression in HPV-negative vs. HPV-positive cervical cancers","volume":"11","author":"Evans","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.intimp.2026.116193_bb1155","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:04:06Z","timestamp":1775189046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":231,"alternative-id":["S1567576926000366"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116193","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116193"}}